NEW YORK – The Jackson Laboratory announced on Wednesday that it has received $2.5 million from the Mark Foundation for Cancer Research to study the influence of host genetics on response to immunotherapy.
The researchers, who are conducting the study in mice, are aiming to generate new insights on which cancer patients will respond positively to immunotherapies, based on their genetic backgrounds. The project, "Dissecting the Genetic Control of Response to Immune Checkpoint Inhibitors in Cancer," has implications for how oncologists prescribe a treatment regimen, the lab noted.